Categories
BLOG

blueberry stock

Bloomberg

We’ve detected unusual activity from your computer network

To continue, please click the box below to let us know you’re not a robot.

Why did this happen?

Please make sure your browser supports JavaScript and cookies and that you are not blocking them from loading. For more information you can review our Terms of Service and Cookie Policy.

Need Help?

For inquiries related to this message please contact our support team and provide the reference ID below.

Bloomberg We’ve detected unusual activity from your computer network To continue, please click the box below to let us know you’re not a robot. Why did this happen? Please make sure your

Blueberries Medical Corp. (BBRRF)

Previous Close 0.0390
Open 0.0410
Bid N/A x N/A
Ask N/A x N/A
Day’s Range 0.0396 – 0.0411
52 Week Range 0.0289 – 0.1420
Volume 15,700
Avg. Volume 64,468
Market Cap 4.727M
Beta (5Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) N/A
Earnings Date N/A
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date N/A
1y Target Est N/A
Fair Value

Subscribe to Premium to view Fair Value for BBRRF

Related Research

Blueberries Medical Announces Approval of Nine Psychoactive Strains, Corporate Update

TORONTO, Oct. 26, 2020 (GLOBE NEWSWIRE) — Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries”), a Latin American licensed producer of medicinal cannabis and cannabis-derived products announced today that the Company received approval from the Colombian Agricultural Institute (“ICA”) for the registration of its nine psychoactive Tetrahydrocannabinol (“THC”) dominant strains with the national cultivar registry. Blueberries today also announced that Mr. Camilo Villalba has resigned as the Chief Executive Officer (“CEO”) of the Company due to unforeseen personal reasons. Blueberries would like to thank Mr. Villalba for his service and significant contribution to the Company. Mr. Villalba will be available to provide consulting services to Blueberries.”It is with great regret that I have to stand down from Blueberries so early in our company’s evolution. I see such enormous potential both with the company and medicinal cannabis sector. However, some extremely unanticipated circumstances have arisen that have forced my hand, and I am unable to carry on. We have achieved tremendous milestones so far, and I would like to thank the board for having given me this opportunity.”The board is pleased to announce that is has appointed Mr. Christian Toro as the Interim CEO of the Company effective October 23, 2020. Mr. Toro will continue to act as the Executive Chairman of Blueberries in addition to assuming the Interim CEO role. With the ongoing Covid-19 crisis, the board has decided it would be inappropriate to appoint a new CEO at present. Instead, the focus will be on reducing costs and preserving capital.Earlier this year, Blueberries implemented extensive cost saving measures of reducing administrative, capital and operational expenditures and preserving working capital to optimize its cost structure and focus on revenue bringing activities. Due to the ongoing impact of the Covid-19 pandemic, Blueberries is continuing its cost saving measures until revenues from sales commence. About Blueberries Medical Corp. Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia and operations currently being established in Argentina. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.Additional information about the Company is available at www.blueberriesmed.com. For more information, please contact:Christian Toro, Chairman and Chief Executive Officer [email protected] Tel: +57 (310) 219 9911Ian Atacan, Chief Financial Officer [email protected] Tel : +1 (416) 562 3220Cautionary Note Regarding Forward-Looking Information This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, to: commencement of commercial production of CBD-dominant oils and products in 2020, successful implementation of full GMP standards at its extraction facility to allow for additional export potential to international markets, achieving additional milestones in 2020 as contemplated, or at all, ability to expand distribution networks, ability to expand and upgrade the Company’s cultivation facilities in Colombia, internal expectations, expectations regarding the ability of the Company to access new Latin American and international markets, the ability to attract and retain new customers, and future expansion plans including development of the cultivation, production, industrialization and marketing of cannabis for commercial and scientific purposes. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Colombia, Argentina and elsewhere; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.Additional information regarding the Company, and other risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s Listing Statement dated January 31, 2019 filed on its issuer profile on SEDAR at www.sedar.com.No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

How He Made $2.8M Trading Stocks Part-Time At Home

Kyle Dennis took a leap of faith and decided to invest his savings of $15K in the stock market — $2.8M later, he owes his success to these strategies

IIROC Trading Halt – MVP

VANCOUVER, BC, Oct. 8, 2020 /CNW/ – The following issues have been halted by IIROC: Company: MediaValet Inc.

Cannabis Industry Investor Presentations Now Available for On-Demand Viewing

Virtual Investor Conferences, in partnership with KCSA Strategic Communications, today announced that the presentations from the September 10th cannabis conference are now available for on-demand viewing at VirtualInvestorConferences.com.

Live Investor Conference & Webinar: Cannabis Industry Companies Present September 10th

Virtual Investor Conferences and KCSA Strategic Communications today announced the agenda for the upcoming Cannabis Industry Virtual lnvestor Conference. Individual investors, institutional investors, advisors and analysts are invited to attend. The program opens at 10:45 AM ET, with the first live webcast at 11:00 AM ET, on Thursday, September 10th.

BLUEBERRIES MEDICAL CORP. to Webcast Live at VirtualInvestorConferences.com September 10th

Blueberries Medical Corp. (CSE: BBM) (OTCQB: BBRRF) (FRA: 1OA), based in Latin America, focused on production of medicinal cannabis and cannabis-derived products, today announced that Camilo Villalba, Co-founder & Chief Executive Office, will present live at VirtualInvestorConferences.com on September 10th.

Blueberries Medical to Webcast Live at VirtualInvestorConferences.com on September 10th

Blueberries Announces Call-in and Webcast Details for its Annual General and Special Meeting (“AGM”)

TORONTO, July 24, 2020 (GLOBE NEWSWIRE) — Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries”), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce call-in numbers and webcast link for the Annual General and Special Meeting of the shareholders of Blueberries Medical Corp. (the “AGM”). The AGM will be held on Friday, July 31, 2020 at 1:00 pm Eastern Time at 82 Richmond Street East, Toronto, Ontario, Canada M5C 1P1.In response to the ongoing global COVID-19 pandemic, the board of directors of Blueberries is advising shareholders not to attend the AGM in-person. After considering recent Provincial and Federal guidance regarding public gatherings and to proactively protect the health and well-being of Blueberries’ shareholders, employees, and service partners who participate in the AGM, the AGM will also be hosted in a virtual setting via webcast and teleconference.In order to streamline the meeting process, the Company strongly encourages shareholders to vote in advance of the meeting using the Form of Proxy or Voting Instruction Form mailed to them with the meeting materials. Comprehensive information with respect to how registered and beneficial shareholders may vote in advance of the meeting is available in Blueberries’ Management Information Circular, also filed on SEDAR.The deadline to vote your proxy in advance of the meeting is 1:00 pm, Eastern Time on Wednesday, July 29, 2020.The webcast and teleconference will allow shareholders to listen to the proceedings and ask questions verbally through the teleconference. Details for shareholders interested in calling-in to the meeting are below. Participants should login and/or dial in approximately 10 minutes prior to the start time.Date and Time: Friday, July 31, 2020 at 1:00 PM Eastern Time Shareholder Access: Call-in No.: 647-723-3984 Toll Free: 1-866-365-4406 (Canada/US) 018000125551 (Colombia) Access Code: 3616167 Webcast: Join Zoom Meeting https://us02web.zoom.us/j/88129348804?pwd=M05BelRzUU9WM0ZvWWxYTGIvTVIzQT09Meeting ID: 881 2934 8804 Passcode: 977183 Dial by your location: +57 1 514 0382 Colombia +57 1 518 9697 Colombia +57 1 518 9698 Colombia +57 2 620 7388 Colombia +57 1 508 7702 Colombia +1 587 328 1099 Canada +1 647 374 4685 Canada +1 647 558 0588 Canada +1 778 907 2071 Canada +1 204 272 7920 Canada +1 438 809 7799 Canada Find your local number: https://us02web.zoom.us/u/kbEv5rH5dp Following the formal proceedings of the AGM, management will provide a business update and presentation. All interested parties are invited to attend the AGM and participate in the management update. About Blueberries Medical Corp. Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.Additional information about the Company is available at www.blueberriesmed.com.For more information, please contact: Camilo Villalba, Chief Executive Officer [email protected] Tel: +57 (313) 483 0131Ian Atacan, Chief Financial Officer [email protected] Tel: +1 (416) 562 3220Cautionary Note Regarding Forward-Looking Information This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward looking statements”) within the meaning of the applicable Canadian securities legislation. All statements, other than statements historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, to: closing of the proposed transactions and achieving milestones in 2019 as contemplated, or at all, ability to expand distribution networks, ability to expand and upgrade the Company’s cultivation facilities in Colombia, internal expectations, expectations regarding the ability of the Company to access new Latin American and international markets, the ability to attract and retain new customers, and future expansion plans including development of the cultivation, production, industrialization and marketing of cannabis for commercial and scientific purposes.These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Colombia, Argentina and elsewhere; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.Additional information regarding the Company, and other risks and uncertainties relating to the Company’s business are contained under the heading “Risk Factors” in the Company’s Listing Statement dated January 31, 2019 filed on its issuer profile on SEDAR at www.sedar.com.No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.

Blueberries Announces Strategic Investor & Closing of $1.0 Million Financing

TORONTO, July 16, 2020 — Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries”), a Latin American licensed producer of medicinal.

Blueberries Announces Strategic Partnership with medcann

Blueberries Medical Corp. (CSE:BBM) (BBRRF) (1OA.F) (the “Company” or “Blueberries”), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that its wholly-owned subsidiary Blueberries SAS entered into a collaboration agreement (the “Partnership”) with Medicanmentos de Cannabis SAS (“medcann”), to develop, and produce Tetrahydrocannabinol (“THC”) cannabis extracts for the international market. Blueberries will develop a Research and Development (“R&D”) project with medcann to produce commercial THC dominant extracts. The Company will utilize its extraction capabilities to process the THC dominant cannabis flower cultivated by medcann.

Blueberries Commences Commercial Sales of Proprietary Cultivars to Local Partners

Blueberries Medical Corp. (CSE:BBM) (BBRRF) (1OA.F) (the “Company” or “Blueberries”), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that it has officially commenced sales of its proprietary cultivars approved by the Colombian Institute of Agriculture (“ICA”). Blueberries has entered into multiple sales agreements to distribute its proprietary genetics to licensed producers located in Bogota Savannah, the region where the Company operates. Under the agreements, the Company will leverage contract growers to produce the Company’s registered non-psychoactive cannabidiol (“CBD”) strains approved by ICA.

Blueberries Medical Announces Joint Venture with QualCann SAS to Export to the US Market

Blueberries Medical Corp. (CSE:BBM) (BBRRF) (1OA.F) (the “Company” or “Blueberries”), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that the Company has entered into a Joint Venture (the “JV”) with QualCann SAS (“QualCann”), an arm’s length third party, to produce extract oil to be commercialized in the United States of America (“US”) market. QualCann is cultivating at least two net hectares of its registered cultivars approved by the Colombian Agricultural Institute (“ICA”) at its facility located in the Bogota Savanna, to deliver high quality dry and ground cannabis flower. The JV, owned 50% by Blueberries and 50% by QualCann, will produce bulk medicinal Cannabidiol (“CBD”) oil extract.

Blueberries Medical Granted Cultivation License for up to 37 Acres of Outdoor Production at Second Cultivation Property, Signs Letter of Intent to Commence Low-Cost Outdoor Production

Blueberries Medical Corp. (CSE:BBM) (BBRRF) (1OA.F) (the “Company” or “Blueberries”), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that the Ministry of Justice and Law of the Republic of Colombia has granted a non-psychoactive cultivation license for the Zipaquira property, making it the Company’s second fully licensed cultivation facility in Colombia. The granted license brings Blueberries closer to being one of larger licensed medicinal cannabis producers for domestic and international distribution. In order to quickly and cost-effectively bring the Zipaquira property into production, the Company has signed a Letter of Intent (“LOI”) to enter into a joint venture with QualCann SAS (“QualCann”) for the development of the property into a low-cost outdoor cultivation facility.

Blueberries Medical Provides Corporate Update

Blueberries Medical Corp. (CSE:BBM) (BBRRF) (1OA.F) (the “Company” or “Blueberries”), a Latin American producer of medicinal cannabis and cannabis-derived products, is providing the following update on the Company’s recent operating activities. In view of the COVID-19 pandemic, we would like to provide an update on our activities at Blueberries. Blueberries has a well-prepared supply chain that is positioned to minimize disruption.

Blueberries Medical Commissions First Line at Extraction Facility; Secures Supply Agreements with Contract Growers; Further Strengthens Management Team

Blueberries has commissioned the first extraction line at its 2,800 m2 (30,138 ft2) state-of-the-art extraction facility, strategically located in Cundinamarca, the region with the highest concentration of licensed cannabis producers. The first extraction line is fully operational and located in a modern and secure industrial park 30 minutes outside of Bogota.

Find the latest BLUEBERRIES MEDICAL CORP (BBRRF) stock quote, history, news and other vital information to help you with your stock trading and investing.